Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of pregabalin and imipramine is used for treating painful polyneuropathy. This combination therapy uses moderate doses of both medications to provide better pain relief than monotherapy with either drug alone. Pregabalin is an anticonvulsant that binds to the α2δ subunit of voltage-dependent calcium channels, while imipramine is a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake. Clinical trials have shown that the combination provides significantly better pain reduction compared to either medication used alone, though it may cause more side effects including dizziness, drowsiness, confusion, and difficulty concentrating.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + imipramine.